Rocket Pharmaceuticals reported a net loss of $40.2 million for the first quarter of 2021. The company's cash, cash equivalents, and investments totaled $466.4 million, expected to fund operations into the second half of 2023. Key pipeline developments include pausing the RP-A501 Danon Disease program for additional risk mitigation and advancing the fifth gene therapy program in Infantile Malignant Osteopetrosis into patient dosing.